Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 7/20 | 0.46 |
| ▸ | EP300 | Q09472 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.45 |
| ▸ | HTR1A | P08908 | 3/20 | 0.45 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | IKBKB | O14920 | 2/20 | 0.43 |
| ▸ | CHUK | O15111 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5937352 | 0.87 | HTR6 (0.48) | HTR6SLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL6709455 | 0.82 | HTR2C (0.59) | HTR6SLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL23228614 | 0.78 | SLC6A2 (0.66) | SLC6A2SLC6A4SLC6A3HTR1AHTR2C | |
| SCHEMBL6790425 | 0.77 | TRPC6 (0.43) | CNR2 | |
| SCHEMBL20201828 | 0.76 | PDE4B (0.43) | EP300HTR2CKDM1ACNR2 | |
| SCHEMBL20204807 | 0.75 | KDM4A (0.46) | HTR2CCNR2 | |
| SCHEMBL6709234 | 0.75 | TRPA1 (0.47) | HTR6SLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL25085586 | 0.75 | HTR6 (0.51) | HTR6SLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL20208255 | 0.75 | DUT (0.42) | HTR2C | |
| SCHEMBL11452948 | 0.75 | HTR6 (0.51) | HTR6SLC6A2SLC6A4SLC6A3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147557-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression | BOUILLOT ANNE (FR) | 2004-07-29 | — | — | US | disclosed |
| EP-1351937-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002055497-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147557-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression | NR1H2, NR1H3, NR1H4 | HTR6 435/4885EP300 680/4885SLC6A2 2350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.